Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure.
Acute, acute-on-chronic and chronic liver diseases are major health issues worldwide, and most cases end with the need for liver transplantation. Up to 90% of the patients die waiting for an organ to be transplanted. Hepatic encephalopathy is a common neuropsychiatric syndrome that usually accompanies liver failure and impacts greatly on the quality of life. The molecular adsorbent recirculating system (MARS) is a recently developed form of artificial liver support that functions on a base of albumin dialysis. It facilitates the dialysis of albumin-bound and water-soluble toxins, allowing the patient to survive and even improving some clinical features of liver failure. The following manuscript reviews the technical features of MARS operation and some of the clinical trials that analyze the efficacy of the system in the therapy of liver diseases.
Medica Sur Clinic and Foundation, Biomedical Research Department,         Liver Research Unit, Mexico City. Mexico.
Ramón A
RA
Kobashi-Margáin
Juan G
JG
Gavilanes-Espinar
Ylse
Y
Gutiérrez-Grobe
Angel A
AA
Gutiérrez-Jiménez
Norberto
N
Chávez-Tapia
Guadalupe
G
Ponciano-Rodríguez
Misael
M
Uribe
Nahum
N
Méndez Sánchez
D000418:Albumins; D006501:Hepatic Encephalopathy / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000150:complications*; D019164:Liver, Artificial; D006435:Renal Dialysis / Q000379:methods*; D016060:Sorption Detoxification / Q000379:methods; D016896:Treatment Outcome
D000418:Albumins